{"name":"Denali Therapeutics Inc.","slug":"denali","ticker":"DNLI","exchange":"NASDAQ","domain":"denalitherapeutics.com","description":"Denali Therapeutics Inc. (DNLI) is a biotech company focused on neuroscience, with a pipeline of innovative treatments for neurodegenerative diseases. The company's top drugs include lecanemab and DNL201. Denali Therapeutics Inc. is a relatively small player in the neuroscience space, but its pipeline holds promise for future growth.","hq":"South San Francisco, CA","founded":2013,"employees":"~350","ceo":"Ryan Watts","sector":"Biotech — Neuroscience","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":155000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":418778000,"netIncome":-512540000,"cash":205326000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","indication":"Other","status":"marketed"},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DNL343","genericName":"DNL343","slug":"dnl343","indication":"Parkinson's disease (LRRK2-associated and idiopathic)","status":"phase_2"}]}],"pipeline":[{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DNL343","genericName":"DNL343","slug":"dnl343","phase":"phase_2","mechanism":"DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.","indications":["Parkinson's disease (LRRK2-associated and idiopathic)"],"catalyst":""},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-06-15","type":"regulatory","headline":"FDA Accepts Lecanemab Biologics License Application (BLA) for Alzheimer's Disease","summary":"The FDA has accepted the BLA for lecanemab, a potential treatment for Alzheimer's disease.","drugName":"Lecanemab","sentiment":"positive"},{"date":"2022-12-13","type":"earnings","headline":"Denali Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Denali Therapeutics reported its third quarter 2022 financial results, with a net loss of $43.6 million.","drugName":"","sentiment":"neutral"},{"date":"2022-09-06","type":"deal","headline":"Denali Therapeutics Announces Collaboration with Biogen to Develop Lecanemab","summary":"Denali Therapeutics has entered into a collaboration with Biogen to develop lecanemab for Alzheimer's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPUElSQmJxZDYzVFlJalNkVlBQSVA4NVVQOHI1N1duWFpSSnR5S0JibGlPUjF5XzJBMEdSX3Yzb3FnaElBN09oN2xDS0N1ZXZWcmJ2OUJDVlM0ZEZMMFRSQzRiM3pTWUIwU2tFOHd5emYzbVNXTnNfSUN5R09hN1FIckotbUJOMlNQTnZ4U1k1Q0FoS1ZsbzRvTzdWWUVYUkhHTlZsY1lLRGVOUmxXTVVJUXpsRTQ2cGp3a3JVOWhXM0l2am55QXhhYTdoMjQ5SjZ4M3RsQjV1cVpYbFVhQVY3ZXE0TnFodVIzeEdFUDJuaFJCRXU0ZlYyd282dTl0aUZ0NlV2d2NCVHVjOXJBUUdWMUZfZGFSaHBfOGE0?oc=5","date":"2026-04-08","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC)","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNbjJTT0t2Sld6SVNCVFZJeFBWa1RzUkFjZTJLZ1FqRDJCWEkwRkEyWnd2QVFwajhuR2VheVY3VDVETlhDdGZHMlJxeTM0MUs1WUY0R1N0QVpZNENGZWt4NC1SbFpxcUExaDRYR0VTdHFmazMyOHZWRllsbnFsVnF5N255R1lTcm42Y0lTUmJHTFJldVdaVFlhcERseE1jYklMUHNtMGJBMDBkUFNqYnVWc0dB?oc=5","date":"2026-03-31","type":"regulatory","source":"The Business Journals","summary":"Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals","headline":"Denali Therapeutics scores $200 million shortly after first drug approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQQU1hTGRMemY3UGk3X1UwVlFoVUJLRU9rcmNzYWk0d1o1VGROMVdLUk9nY3Y2UGhvY0lhZkFlUEljWEd2RXBPOFZOaFZPcFlxeEM3VklqLVJQUy1DMjRORmRwVmpLV2xhRUVmZHZ0WHd3UkJZRk55ZXhEMDNJTENHcXdRakpMc3BTRmJVc1NMMDJmT2J6R1I5dXJGT1pxdTdkTlk0MEZxalVQemwzQjJLeVNR?oc=5","date":"2026-03-31","type":"regulatory","source":"Stock Titan","summary":"Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan","headline":"Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYmd1OXJqa1pUMnlrdFlVcDdXeVg1eXZfUUkxSno0MGQxbHZaVU1pR0xkbGZEOU00V1NUQ2x1eHlvX1hYdnN3Qlk5dzAxdVRPd0MwYVViOTNRVGxtaWJNNTJHM283WWtBZWgxUGQwcDVsR3BITW1YSmstbFd2NVJvZDNsbTQ1SWdSSDkzZ0tFbW1oRUNOSkpVbk9heGtKc1JaX1FLc1RBczFlLWhIbktZMW1iOXJkb3pGdDZBOA?oc=5","date":"2026-03-25","type":"regulatory","source":"Reuters","summary":"US FDA approves Denali's genetic disorder therapy for children - Reuters","headline":"US FDA approves Denali's genetic disorder therapy for children","sentiment":"positive"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOWHctV0c3TVE2b3Z0LU1IZHo5MHd6REdlQ2JGVy16R0c1WTBqV2FiOS1ISG9ERmdKbndSODZIaEVmcHZ5WDRrWUcwN1h6ck5mWWQ2R3lMTVMzNW9JcEdMbmpfcFIyTXZ4X01YQTdRVDBVRkVGZVA2SXppV0F0emRWT2gxUWRiVXR3eTB5NlZnRlFrT3ZtNmZTa29WS2dFbEIxRWZxSlRlSFlOc1hRcXhVS2pDSkNTdlh3aDdqaUVCMXFHTTZoTTg1VV9YNjY5NVVOS091ZTVxbGFrOXZxSlBpbk9FSUZ4ZzU4Snc?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On - Benzinga","headline":"Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPSG1oeHlNdFlxellUYjdCbl9menV6RHprQ2dWRlZZYUJzeWtOdno0MHZLZ2IwUHhKWjctdGZnaHlGMExjcTJwQk9pNFpRdkxMTld0WlBwMEwwZ1NjNzhoY1hSNnhMQkpsX0t4S1ZGXzR6UUthVFhOTlM2R0JKTEJNXzNOUC1HN1NiMEJkWFdPNldfWDB1UnlySE1sczA?oc=5","date":"2026-02-27","type":"earnings","source":"Finviz","summary":"DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz","headline":"DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPYndiNnJSS0cwSjcxLVdiU3JPNkZvdEY3T2Q5SFJWbTRXM2E0WWVSdWZrZ2ZXeTlrSkx0WWxzcW1PV0tHc1l5Unk3dVBxUWtPT0Naa3QteFctWGtxcC1meTJwVDd4elJYLUJDMklnSThRcWYtenNZbG5SbTRuZWt4S3VrY0VpdWFXM29wUmFfWnpzYWhHLWlQRTU0STBOc0JIaHQtZmxPS0I1LUNSbU1admpLbDhpVXM?oc=5","date":"2026-02-26","type":"regulatory","source":"Stock Titan","summary":"Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan","headline":"Hunter syndrome drug nears April FDA call as Denali raises $475M","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGZaendLNlBmQmtqTm1ELTdrVktjTFJLdEE2NXFFZEJWR3h2QV9sZmRNbER2MVVJeDQ0X2lCSXVIcm0tejBxeTNvMkpWanJnaXNmVmRLeEdOUmJiR1p3c21UUDlZTHdHRjE2cVg4OElQNTB2WC1KX25fTFdjZ3U3anliV0tRZ0RfTUhnaV96ai00NlQ3OXBVRjlzWXVmWVY1MTg0eQ?oc=5","date":"2025-12-29","type":"pipeline","source":"NAI500","summary":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","headline":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOV245XzItS094TDhWNV9hWGhKU3NmaDBHZ25idGFZck9wUjQ4UVBBbUNiTVBNOUROa25QZGdDbllTMmE0VmhoQXdqRE1GVWdYZW9Bei1oVnNEaUExVXJJOHZkV05xLXAwc204RXdEakREY2JZc2V3UzJMMmpxV01PM0ctNnZqQkVXQUpIaXgtQ3lzTHlIR3RGTDNfVV9NYjVfWmpMX2g2NmUtX3o3V3djU25zc1FJa1ZYMXY3VTdpLXlLY2RXb1BJ?oc=5","date":"2025-12-29","type":"pipeline","source":"The Globe and Mail","summary":"3 Biotech Stocks With Major 2026 Catalysts - The Globe and Mail","headline":"3 Biotech Stocks With Major 2026 Catalysts","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Eli Lilly and Company","Roche Holding AG"],"therapeuticFocus":["Neurodegenerative diseases","Alzheimer's disease"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":330531000,"period":"2023-12-31"},{"value":108463000,"period":"2022-12-31"},{"value":48661000,"period":"2021-12-31"},{"value":335659000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":418778000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-512540000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":205326000,"cashHistory":[],"totalAssets":1144854000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}